Studying how immunotherapy affects the immune system in early-stage cancer
Part of Cancer clinical trials.
This trial looks at how your immune system responds to immunotherapy given before surgery for early-stage solid tumors (like lung, head and neck, melanoma, or bladder cancer). The goal is to understand why some people respond better, so doctors can improve treatment for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an early-stage solid tumor that can be treated with immunotherapy before surgery.
- You have not started immunotherapy yet.
- You have a stored tumor sample from an earlier biopsy that can be tested.
- You are in good enough health to walk around and take care of yourself (ECOG score 0-2).
- You must be covered by French Social Health Insurance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This study watches people with solid tumors who are starting immunotherapy for the first time. It aims to predict and better understand side effects and how well the treatment works, to help doctors manage care more effectively.
This study looks at what makes some cancers more “noticeable” to the immune system. It may help researchers design better future immunotherapy by collecting information (often including blood samples) from people with different cancers.
This study follows people who are starting their first immune “checkpoint” treatment for a solid cancer. It collects clinic information and lab results to understand how patients respond and what factors matter most.
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Hear when a new Solid Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.